Who We Are
The ADMETRx team comprises a wealth of scientific expertise and industry experience including HTS methodology as well as customized ADME problem solving. The team is singularly focused on achieving customer drug discovery goals through novel data integration and preclinical profiling methodologies.
Company Principals
Philip S. Burton, PhD
Co-Founder, CEO, and CSO
psburton@admetrx.com
With 25 years of experience in medicinal and biopharmaceutical chemistry and drug absorption, Phil is an internationally recognized thoughtleader in modeling drug absorption and a frequent invited lecturer to numerous national and international symposia. Phil received his PhD in Medicinal Chemistry (Prof. Raymond Bergeron) from the University of Florida. After completing a Postdoctoral Fellowship with Prof. Konrad Bloch in the Department of Chemistry at Harvard University, he joined The Upjohn Company (now Pfizer) in 1983 as a research scientist. He remained with Upjohn through its mergers with Pharmacia and Monsanto as a Senior Scientist in the Drug Absorption and Transport Group. He also led the Computational Biopharmaceutics Group from its inception in 2000 to 2003. Phil received the Meritorious Manuscript Award in both 1994 and 1998 from the American Association of Pharmaceutical Scientists (AAPS), and was elected Fellow of the AAPS in 1999. He is currently a member of the The American Chemical Society, AAPS, ASPET, The New York Academy of Sciences, and AAAS. He has served as Associate Editor for the Journal of Pharmacology and Experimental Therapeutics since 2000, and is a member of the editorial board of the Journal of Pharmaceutical Sciences and Chemical Biology and Drug Discovery.
Jay T. Goodwin, PhD
Co-Founder, President, and COO
jtgoodwin@admetrx.com
Jay received his PhD in Organic Chemistry (Prof. David Lynn) from the University of Chicago in 1992 prior to completing an NIH Postdoctoral Fellowship in Bioorganic Chemistry with Prof. Gary Glick in the Department of Chemistry at the University of Michigan. He joined the Drug Absorption and Transport Group at Pfizer (formerly The Upjohn Company and, later, Pharmacia) in 1995, and played a critical role in developing the multidisciplinary focus on in silico ADME, as a core member of the Computational Biopharmaceutics and Emerging Technology In Silico Groups from their inception. He is a member of The American Chemical Society, The American Association of Pharmaceutical Scientists, and The Association for Laboratory Automation. With 15 years of experience in bioorganic, biopharmaceutical, and medicinal chemistry within big pharma, Jay has become known as a thoughtleader in his field and is a frequent invited lecturer at national and international biopharmaceutical symposia.